Broken biopharm
The engine of biopharmaceutical innovation is broken, according to Eli Lilly's Chairman and CEO, John C. Lechleiter.
The engine of biopharmaceutical innovation is broken, according to Eli Lilly's Chairman and CEO, John C. Lechleiter. Speaking to the City Club of San Diego (CA, USA), which included many business leaders from San Diego's biotech sector, Lechleiter explained that repowering pharmaceutical innovation is an "urgent" need. "At a time when the world desperately needs more new medicines, we're taking too long, spending too much and producing far too little," he said.
He believes that the biotech industry is wasting its potential. Although he acknowledged that several major challenges are facing the industry, such as a loss of trust in product safety and the pressures of the healthcare system, he added that it was a waste of time to complain about these.
Instead, companies should change the way they develop new medicines. In particular, he suggested that collaboration (i.e., working with large and small enterprises, as well as academic and government researchers worldwide) and competency (i.e., taking advantage of advanced scientific tools) could help to boost medical innovation. He also added that patients and improved outcomes should be placed at the center of research from the start of the drug development process.
According to Lechleiter, reinventing biopharm R&D will help regain the public's trust, address the concerns of regulators and demonstrate to policymakers the value that innovative medicines can play.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
